Bio-Techne Obtains Reimbursement Contract With Humana for Exosome Diagnostics Prostate Biopsy Test

Mar 01, 2021

|

NEW YORK ─ Bio-Techne on Monday announced that Humana, a Medicare Advantage provider, has awarded a contract effective April 1 for coverage of its ExoDx Prostate (EPI) test for men performed at its Exosome Diagnostics laboratory.

Minneapolis, Minnesota-based Bio-Techne noted that Humana serves an estimated 20 million patients in the US.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Bio-Techne Obtains Reimbursement Contract With Humana for Exosome Diagnostics Prostate Biopsy Test

To read the full story....

Breaking News

Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor

FDA Grants First ASCA Accreditations to Labs to Perform Premarket Testing

Top Five Articles on 360Dx Last Week: NIH RADx, LumiraDx, Abbott, And More

Amazon to Give Out $12M Under Next Phase of AWS Diagnostics Development Initiative

Lucira Health Nabs OTC EUA for SARS-CoV-2 Test, Expects Q1 Revenues of up to $4.5M

DiaSorin to Acquire Luminex for $1.8B

What's Popular?

DiaSorin to Acquire Luminex for $1.8B

Siemens Healthineers Gets CE Mark for Point-of-Care High-Sensitivity Cardiac Troponin I Test

Novacyt in Dispute with UK Department of Health and Social Care Over Coronavirus Test Contract

Hologic to Acquire Finnish MDx Firm Mobidiag for Approximately $795M

FDA Issues First EUA for COVID-19 Antibody Test Using Self-Collected Blood Samples

Sponsorships